Intellia Therapeutics Inc buy Wells Fargo & Company
Start price
28.02.25
/
50%
€9.50
Target price
28.02.26
€48.09
Performance (%)
-18.21%
Price
29.12.25
€7.77
Summary
This prediction is currently active. The prediction for Intellia Therapeutics Inc disappoints with a performance of -18.21%. This prediction currently runs until 28.02.26. The prediction end date can be changed by Wells_Fargo___Compan at any time. Wells_Fargo___Compan has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Intellia Therapeutics Inc | -5.887% | -5.887% |
| iShares Core DAX® | 0.323% | 2.208% |
| iShares Nasdaq 100 | 0.145% | -0.987% |
| iShares Nikkei 225® | 0.091% | -1.421% |
| iShares S&P 500 | 0.371% | -0.469% |
Comments by Wells_Fargo___Compan for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Wells Fargo & Company from $60.00 to $50.00. They now have an "overweight" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Stopped prediction by Wells_Fargo___Compan for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€9.49
08.08.25
08.08.25
-
08.08.26
08.08.26
-18.11%
29.12.25
29.12.25
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€10.22
10.01.25
10.01.25
€58.40
10.01.26
10.01.26
-23.97%
29.12.25
29.12.25
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€13.35
18.11.24
18.11.24
€66.07
18.11.25
18.11.25
-46.02%
19.11.25
19.11.25